Clinical trial · Interventional
Assessement of Viral Shedding Duration After a Respiratory Tract Infection in Oncology and Hematology Patients
NCT03389997CI-TRIAL-00076291ONCOVIRcompletedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to assess the duration of the viral shedding in hematology and oncology patients after a respiratory tract viral infection. This duration has not been much studied in that population whereas it is probably longer than that in immunocompetent patients. Thereby it may be a source of transmission amongst these immunocompromised patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Respiratory Tract Viral Infection | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| nasal swabs | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Nasal carriage of virus after a viral respiratory tract infection
- timeFrame
- Up to 1 year
- description
- Iterative nasal swab to assess the duration of that carryiage
Secondary outcomes (13)
- measure
- Prevalence of upper and lower respiratory tract infections
- timeFrame
- 2 years
- measure
- Prevalence of viral coinfections
- timeFrame
- 2 years
- measure
- Prevalence of bacterial coinfections
- timeFrame
- 2 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patient with solid organ cancer or haematological malignancy with or without chemotherapy * Having symptoms of upper and/or lower respiratory tract infection * Virus detected by PCR in nasal sample * Signature of consent Exclusion Criteria: * Hematological stem cell and solid organ recipients * No health insurance * protected people
References
Publications (0)
Data not yet available
No reference posted for this study.